Skip to main content

AMV564-301 A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

NCT04128423

A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Associated Conditions

Multiple Tumor Types

Principal Investigator

George Simon

Sponsor

Amphivena Therapeutics

The purpose of this clinical research study is to learn more about the safety of AMV564, and to learn how AMV564 affects your cancer-specific cells and other blood cells. In addition, the study will look at how long AMV564 can be measured in your blood to better understand how your body processes AMV564.

This study is currently enrolling.